ZA93549B - Azabicyclo compounds as calcium channel antagonists - Google Patents

Azabicyclo compounds as calcium channel antagonists

Info

Publication number
ZA93549B
ZA93549B ZA93549A ZA93549A ZA93549B ZA 93549 B ZA93549 B ZA 93549B ZA 93549 A ZA93549 A ZA 93549A ZA 93549 A ZA93549 A ZA 93549A ZA 93549 B ZA93549 B ZA 93549B
Authority
ZA
South Africa
Prior art keywords
calcium channel
channel antagonists
azabicyclo compounds
azabicyclo
compounds
Prior art date
Application number
ZA93549A
Other languages
English (en)
Inventor
Barry Sidney Orlek
Thomas Henry Brown
David Gwyn Cooper
Original Assignee
Smithline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithline Beecham Plc filed Critical Smithline Beecham Plc
Publication of ZA93549B publication Critical patent/ZA93549B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA93549A 1992-01-28 1993-01-26 Azabicyclo compounds as calcium channel antagonists ZA93549B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929201751A GB9201751D0 (en) 1992-01-28 1992-01-28 Compounds

Publications (1)

Publication Number Publication Date
ZA93549B true ZA93549B (en) 1994-09-22

Family

ID=10709351

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA93549A ZA93549B (en) 1992-01-28 1993-01-26 Azabicyclo compounds as calcium channel antagonists

Country Status (9)

Country Link
EP (1) EP0625981A1 (de)
JP (1) JPH07503462A (de)
KR (1) KR950700305A (de)
AU (1) AU3364593A (de)
CA (1) CA2128536A1 (de)
GB (1) GB9201751D0 (de)
MX (1) MX9300406A (de)
WO (1) WO1993015080A1 (de)
ZA (1) ZA93549B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9314973D0 (en) * 1993-07-20 1993-09-01 Smithkline Beecham Plc Medicaments
UY25225A1 (es) 1997-10-29 2000-12-29 Smithkline Beecham Plc Derivados de pleuromutilina utiles como agentes antimicrobianos
AU1600599A (en) 1998-02-27 1999-09-15 Warner-Lambert Company Heterocyclic substituted aniline calcium channel blockers
US6166052A (en) * 1998-03-11 2000-12-26 Warner-Lambert Company Heteroaryl alkyl alpha substituted peptidylamine calcium channel blockers
EP1345937B1 (de) 2000-12-22 2005-09-28 Almirall Prodesfarma AG Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
ES2203327B1 (es) 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
EP2217597B1 (de) 2007-10-01 2011-03-30 Comentis, Inc. 1h-indol-3-carbonsäure-chinuclidin-4-ylmethylesterderivate als liganden für den nikotinischen alpha-7-acetylcholinrezeptor zur behandlung von alzheimer-krankheit
JP2017524736A (ja) 2014-07-11 2017-08-31 アルファーマゲン,エルエルシー アルファ7−ニコチン性アセチルコリン受容体活性を調節するためのキヌクリジン化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1250534A (de) * 1969-03-03 1971-10-20
GB9005737D0 (en) * 1990-03-14 1990-05-09 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
WO1993015080A1 (en) 1993-08-05
AU3364593A (en) 1993-09-01
CA2128536A1 (en) 1993-08-05
GB9201751D0 (en) 1992-03-11
EP0625981A1 (de) 1994-11-30
KR950700305A (ko) 1995-01-16
JPH07503462A (ja) 1995-04-13
MX9300406A (es) 1994-07-29

Similar Documents

Publication Publication Date Title
ZA93550B (en) Azabricyclic compounds as calcium channel antagonists
GB9315962D0 (en) Azabicyclic compounds
AU3364493A (en) Compounds as calcium channel antagonists
AP9300562A0 (en) Novel compounds
ZA93549B (en) Azabicyclo compounds as calcium channel antagonists
GB9202779D0 (en) Novel compounds
ZA948232B (en) Amine derivatives as calcium channel antagonists
GB9203476D0 (en) Novel compounds
EP0465191A3 (en) Bicyclic sulfur-containing compounds
GB9220893D0 (en) Azabicyclo compounds
GB9208133D0 (en) Azabicyclo compounds
ZA939514B (en) Piperidine derivatives as calcium channel antagonists
GB9303720D0 (en) Azabicyclo compounds
IE900471L (en) Calcium antagonists
ZA975446B (en) Substituted azabicyclic compounds
GB9201483D0 (en) Novel compounds
GB9202931D0 (en) Novel compounds
GB9200712D0 (en) Novel compounds
GB9201290D0 (en) Novel compounds
GB9201291D0 (en) Novel compounds
GB9201413D0 (en) Novel compounds
GB9204996D0 (en) Novel compounds
GB9201506D0 (en) Novel compounds
GB9201507D0 (en) Novel compounds
GB9201957D0 (en) Novel compounds